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REPORT
Recessive Mutations in TRMT10C Cause Defects
in Mitochondrial RNA Processing
and Multiple Respiratory Chain Deficiencies
Metodi D. Metodiev,1,10 Kyle Thompson,2,10 Charlotte L. Alston,2 Andrew A.M. Morris,3,4
Langping He,2 Zarah Assouline,5 Marle`ne Rio,5 Nadia Bahi-Buisson,5 Angela Pyle,6 Helen Griffin,6
Stefan Siira,7 Aleksandra Filipovska,7 Arnold Munnich,1,5 Patrick F. Chinnery,6,8,9 Robert McFarland,2
Agne`s Ro¨tig,1,* and Robert W. Taylor2,*
Mitochondrial disorders are clinically and genetically diverse, with mutations in mitochondrial or nuclear genes able to cause defects in
mitochondrial gene expression. Recently, mutations in several genes encoding factors involved in mt-tRNA processing have been iden-
tified to cause mitochondrial disease. Using whole-exome sequencing, we identified mutations in TRMT10C (encoding the mitochon-
drial RNase P protein 1 [MRPP1]) in two unrelated individuals who presented at birth with lactic acidosis, hypotonia, feeding difficulties,
and deafness. Both individuals died at 5months after respiratory failure.MRPP1, alongwithMRPP2 andMRPP3, form themitochondrial
ribonuclease P (mt-RNase P) complex that cleaves the 50 ends of mt-tRNAs from polycistronic precursor transcripts. Additionally, a stable
complex of MRPP1 and MRPP2 has m1R9 methyltransferase activity, which methylates mt-tRNAs at position 9 and is vital for folding
mt-tRNAs into their correct tertiary structures. Analyses of fibroblasts from affected individuals harboring TRMT10Cmissense variants
revealed decreased protein levels of MRPP1 and an increase in mt-RNA precursors indicative of impaired mt-RNA processing and defec-
tive mitochondrial protein synthesis. The pathogenicity of the detected variants—compound heterozygous c.542G>T (p.Arg181Leu)
and c.814A>G (p.Thr272Ala) changes in subject 1 and a homozygous c.542G>T (p.Arg181Leu) variant in subject 2—was validated
by the functional rescue of mt-RNA processing and mitochondrial protein synthesis defects after lentiviral transduction of wild-type
TRMT10C. Our study suggests that these variants affect MRPP1 protein stability and mt-tRNA processing without affecting m1R9 meth-
yltransferase activity, identifying mutations in TRMT10C as a cause of mitochondrial disease and highlighting the importance of RNA
processing for correct mitochondrial function.Mitochondrial respiratory chain deficiencies lead to in-
sufficient ATP production from oxidative phosphorylation
(OXPHOS), resulting in a wide range of clinical presenta-
tions broadly recognized as ‘‘mitochondrial disorders.’’
Mitochondrial diseases are genetically diverse, owing to
the necessary expression, co-ordination, and activity of fac-
tors encoded by both the mitochondrial and nuclear ge-
nomes for proper mitochondrial function. The 16.6 kb
human mitochondrial DNA (mtDNA) encodes only 22
tRNAs, 2 rRNAs, and 13polypeptides that are essential com-
ponents of four of the five OXPHOS complexes.1 The re-
maining subunits of the respiratory complexes and all of
the factors involved in mtDNA expression and mainte-
nance are encoded by the nuclear genome, synthesized in
the cytosol, and imported into mitochondria. Thus, there
are a large number of potential genetic causes of mito-
chondrial disease, which has often complicated attempts
to identify the correct genetic diagnosis. The advent of
next generation sequencing has greatly expanded the list
of known gene mutations associated with mitochondrial1INSERM U1163, Universite´ Paris Descartes-Sorbonne Paris Cite´, Institut Imag
for Mitochondrial Research, Newcastle University, Newcastle upon Tyne NE2 4
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(mt)-tRNA processing and maturation.3,4
In mammalian mitochondria, all mt-tRNAs required for
mitochondrial protein synthesis are encoded by the mito-
chondrial genome. Transcription of mtDNA produces long
polycistronic transcripts that require further processing.
Most mitochondrial open reading frames are separated
by at least one mt-tRNA gene, with the structure of mt-
tRNAs acting as ‘‘punctuation’’ marks in the transcript5
prior to mt-tRNAs being excised at the 50 end by the RNase
P complex and at the 30 end by the RNase Z enzyme. The
mitochondrial RNase P in animals is composed of three
proteins, MRPP1, MRPP2, and MRPP36 (encoded by
TRMT10C [MIM: 615423], HSD17B10 [MIM: 300256],
and KIAA0391 [MIM: 609947], respectively), whereas
RNase Z is encoded by a single gene, ELAC2 (MIM:
605367).7–10 In addition to cleavage from the polycistronic
transcripts, mt-tRNAs undergo many further modifica-
tions, with at least 30 different modified residues re-
ported.3,11 One crucial modification is m1R9 methylation,ine, 75015 Paris, France; 2Institute of Neuroscience, Wellcome Trust Centre
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inwhich is probably important for the correct folding ofmost
mt-tRNAs. In the case of mt-tRNALys, the unmodified
in vitro transcript folds into an extended bulged
hairpin,12 but with the sole modification of N1 methyl-
ation of adenosine 9 (m1A9), the tRNA adopts the classic
cloverleaf structure.13 It has been demonstrated that
MRPP1 and MRPP2 can form a stable sub-complex that
is active as a methyltransferase and is uniquely able to
methylate both adenosine and guanine nucleotides at po-
sition 9.7,14 19 of the 22 mt-tRNAs contain either A or G
at position 9 and it is likely that all of these are subject to
m1R9 methylation.7,11,14
We studied two children with suspected mitochondrial
disease from unrelated families. Subject 1 (male) was the
second child of healthy, non-consanguineous, white
British parents, with a healthy older sister. He was born
at term by a normal vaginal delivery after a normal preg-
nancy with a birth weight of 3.7 kg. He did not require
resuscitation but was noted to be hypotonic and weak
soon after birth. He fed poorly and gained weight slowly,
partly due to gastro-esophageal reflux. Neonatal screening
revealed significant hearing impairment subsequently
confirmed to be sensorineural deafness. He was also found
to have a raised plasma alanine transaminase of 439 U/L
(normal range 4–45 U/L). Blood lactate levels ranged
from 5 to 10 mmol/L (normal range 0.7–2.1 mmol/L)
and his CSF lactate level was also elevated at 4.8 mmol/L.
Ophthalmological examination, echocardiography, and
anMRI were all normal, though the latter was of poor qual-
ity. There was a clinical suspicion of craniosynostosis and a
lateral skull X-ray appeared to show fused sutures but no
further investigations were undertaken. Ultrasound of
the kidneys was normal. Blood spot acylcarnitine analysis
and plasma biotinidase were normal, plasma amino acid
analysis was normal with the exception of a raised alanine
concentration, and urine organic acid analysis was normal
apart from a raised lactate concentration. He deteriorated
rapidly, requiring tube feeding, and at the age of 4 months
suffered rhinovirus bronchiolitis requiring ventilatory sup-
port with CPAP. It proved impossible to wean him off
ventilatory support and he died at 5.5 months of age after
withdrawal of this support.
Subject 2 (female) was the second child of unrelated par-
ents of Kurdish origin with a healthy older brother. She was
born at term by caesarean delivery, after a normal preg-
nancy, weighing 3.05 kg. Hypotonia, poor sucking, and
feeding difficulties were evident from early in the neonatal
period and hyperlactatemia (7.4 mmol/L; normal range
0.90–1.70 mmol/L) with a high lactate to pyruvate ratio
(170; normal range 30–50) was recorded at 1 month. She
gained weight poorly and nasogastric feeding was
commenced at 3 months. At 3.5 months, echocardiogra-
phy demonstrated left ventricular hypertrophy and lum-
bar puncture revealed elevated CSF lactate (3.1 mmol/L;
control< 2.2 mmol/L). She also had significantly impaired
liver function (AST: 84 UI/L, normal range 15–60; ALT:
52 UI/L, normal range 7–40; gGT: 262 UI/L, normal range994 The American Journal of Human Genetics 98, 993–1000, May 5, 2016
Figure 1. Autosomal-Recessive TRMT10C Variants Affect Evolutionarily Conserved Amino Acids and Are Associated with Mitochon-
drial Dysfunction
(A–G) Histopathological analysis of skeletalmuscle sections from subject 1 showing (A) hematoxylin and eosin (H&E) staining, (B)modi-
fied Gomori trichrome staining, (C) succinate dehydrogenase (SDH) histochemistry, (D) NADH-tetrazolium reductase histochemistry,
(E) cytochrome c oxidase (COX) histochemistry, and (F) sequential COX-SDH histochemistry, which clearly illustrates a mosaic pattern
of COX deficiency (G). Pedigree and sequencing chromatograms for the families of subject 1 (left) and 2 (right) showing segregation of
biallelic TRMT10C variants.
(H) Sequence alignment depicting the evolutionary conservation of the affected amino acids (bold).6–25 UI/L). Brain MRI was undertaken at 2 months of age
and was of poor quality but showed findings suggestive of
bifrontal polymicrogyria. Acoustic oto-emissions were
abnormal at 4 months, suggesting deafness. Unfortu-
nately, auditory evoked potential was not done. She died
at 5 months of age from respiratory distress.
Informed consent for diagnostic and research studies
was obtained for both subjects in accordance with the
Declaration of Helsinki protocols and approved by local
Institutional Review Boards in Newcastle upon Tyne,
UK, and Paris, France. Biochemical analysis of skeletal
muscle samples identified clear mitochondrial enzyme de-
fects involving both complex I and IV in both subjects,
whereas complex III activity was normal in subject 1 but
decreased in subject 2; both cases showed sparing of
complex II activity (Table 1). Histopathological analysis
of muscle from subject 1 revealed evidence of subsarco-
lemmal mitochondrial accumulation (ragged red fibers)
and a mosaic pattern of cytochrome c oxidase (COX) defi-
ciency (Figures 1A–1F).
Analysis of muscle DNA from both subjects excluded
mtDNA abnormalities (mtDNA rearrangements and point
mutations) and mtDNA copy number was shown to be
normal in each case (data not shown). Whole-exome
sequencing via previously described methodologies
and bioinformatic filtering pipelines2,15 identified biallelic
variants in TRMT10C (MIM: 615423; GenBank: NM_
017819.3; also known as MRPP1 and RG9MTD1). Com-The Amepound heterozygous c.542G>T (p.Arg181Leu) (ClinVar:
SCV000264779.0) and c.814A>G (p.Thr272Ala) (ClinVar:
SCV000264780.0) variants were identified in subject 1,
whereas subject 2 was homozygous for the c.542G>T
(p.Arg181Leu) variant, also identified in subject 1. Sanger
sequencing was undertaken to validate the variants and
confirm that these segregated with disease in each family
(Figure 1G). Both identifiedTRMT10C variants are predicted
to result in amino acid substitutions affecting evolutionarily
conserved residues (Figure 1H) and are rare: the c.542G>T
(p.Arg181Leu) variant is present on the ExAC database
(10/120,324 alleles) and ESP6500 (1/11,824 alleles) whereas
the c.814A>G (p.Thr272Ala) TRMT10C variant is absent on
ExAC, ESP6500, and COSMIC. In silico predictions via SIFT,
PolyPhen-2, andaGVGDsuggest that thebiophysico impact
of the p.Arg181Leu substitution are relatively benign but
that the proximity of the Arg181 residue to the TRM10-
type domain (predicted fromMet191) couldhint at a crucial
structural role that only an arginine residue can perform. In
silico modeling of the TRMT10C variants via RaptorX and
Phyre2 produced disparate predictions of MRPP1 protein
structure and thus could not be used to indicate any poten-
tial misfolding as a consequence of the variants.
To investigate the functional effects of the identified
TRMT10C variants, Western blot and mitochondrial pro-
tein synthesis assays were performed in fibroblast cell lines
derived from both affected individuals and age-matched
control subjects. These data showed that the steady-staterican Journal of Human Genetics 98, 993–1000, May 5, 2016 995
Figure 2. Mutant MRPP1 Protein Is Unstable and Leads to Impaired Mitochondrial Protein Synthesis Causing Multiple Respiratory
Chain Defects
(A) Western blot analyses of mitochondrial extracts from control and affected individuals using commercial MRPP1-, MRPP2-, and
MRPP3-specific antisera. Porin (VDAC1) was used as a loading control. Asterisk (*) indicates cross-reacting band.
(B) Western blot analyses of protein extracts from affected fibroblasts showing decreased levels of MRPP1 and subunits of mitochondrial
respiratory complexes I (NDUFB8) and IV (COXI and COXII).
(C) Blue-native PAGE analysis of OXPHOS complex assembly using mitochondrial extracts in 1% DDM from control and subject fibro-
blasts (as described previously16) demonstrated decreased assembly of OXPHOS complexes I and IV and to a lesser extent complex III in
subject fibroblasts.
(A–C) Samples (25 mg protein) were fractionated through 4%–16% native gels (Thermo Fisher Scientific) transferred onto PVDF mem-
branes and subjected to western immunoblotting. Subunits from individual OXPHOS complexes were detected using specific antibodies:
complex I (NDUFA13), complex II (SDHA), complex III (UQCRC2), complex IV (COXI), and complex V (ATP5B).
(D) In vitro labeling of de novo synthesized mitochondrial translation products with EasyTag EXPRESS35S Protein Labeling Mix (Perkin
Elmer) followed by fractionation through a 17% SDS-Polyacrylamide gel and autoradiography (as described previously32). Coomassie
brilliant blue staining of the gels was used to demonstrate equal loading.levels of MRPP1 were markedly decreased in the subject
cell lines, suggesting that the variants affect the stability
of the protein (Figure 2A). On the other hand, levels of
MRPP2 and MRPP3, the other two subunits of RNase P,
were unchanged in fibroblasts from affected individuals
(Figure 2A). The loss of MRPP1 protein level correlates
with decreased steady-state levels of subunits of complex
I (NDUFB8) and complex IV (COXI) (Figure 2B), in agree-
ment with the multiple respiratory chain defects observed
in muscle. We used blue native PAGE to determine the ef-
fects on the assembly and stability of the respiratory chain
complexes16 and show a marked decrease of fully assem-
bled complex I and complex IV, with a slight decrease in
complex III levels (Figure 2C). The low steady-state levels
of mtDNA-encoded proteins was due to impaired mito-
chondrial protein synthesis in subject fibroblasts as
demonstrated by reduced incorporation of 35S-labeled
methionine and cysteine (Figure 2D).
Because MRPP1 is known to be an essential subunit
of the mitochondrial RNase P,6 which is responsible for
50 cleavage of mt-tRNAs from the polycistronic mitochon-
drial transcripts, we investigated whether fibroblasts from
affected individuals showed evidence of impaired mito-996 The American Journal of Human Genetics 98, 993–1000, May 5,chondrial RNA processing. Northern blot analyses showed
an increase in RNA precursor RNA19 when detected with
either anMT-ND1 orMT-RNR2 probe (Figure 3A). However,
the steady-state levels of the mature mRNAs were not
significantly affected. No increase in precursors of MT-
CO2 or MT-CO3 were observed, although the steady-state
levels of mature MT-CO3 appeared to be slightly decreased
in subject 2 (Figure 3A).
Processing of mt-tRNAs at the 30 end is carried out by
ELAC2.7,8,10 Because both subjects had functional copies
of ELAC2, it would be expected that the mt-tRNAs would
be processed at the 30 end, but not at the 50 end, resulting
in mt-mRNAs with an uncleaved mt-tRNA at the 30 end.
The resolution of the Northern blots for mt-mRNAs was
not sufficient to distinguish between mature mRNA and
these pre-processed transcripts, thus, high-resolution
Northern blot experiments were performed to assess the
levels of mature mt-tRNAs (Figure 3B). Surprisingly, the
steady-state levels of mt-tRNAs were not significantly
altered in the affected individuals relative to controls, sug-
gesting that the severe mitochondrial translation defect
was not due to absence of cleaved mt-tRNAs. However,
mt-tRNAPhe andmt-tRNALeu(UUR) appeared to have slightly2016
Figure 3. TRMT10C Variants Lead to Altered RNA Processing but Do Not Affect Methylation at Position 9
(A) Northern blot analyses of mt-mRNA steady-state levels using radiolabelled probes specific for MT-ND1, MT-RNR2 (16 s rRNA),
MT-CO2, and MT-CO3. Asterisk (*) denotes putative mtRNA precursors.
(B) High-resolution Northern blot analyses of mt-tRNAs using radiolabelled oligonucleotide probes against mt-tRNAs with 5S rRNA as a
loading control (performed as described previously33).
(C) Primer extension analysis of m1G9 in tRNALeu(UUR) using a radiolabeled primer (50- TTATGCGATTACCGGGCTCTGC-30) annealing 1
base downstream of the modified residue. Primer and 3 mg RNA were denatured at 95C for 5 min and cooled on ice. Primer extensions
were carried out using AMV reverse transcriptase (Thermo Fisher Scientific) at 45C for 1 hr and stopped by heating at 85C for 15 min.
After ethanol precipitation, the samples were analyzed by fractionation through a 12% polyacrylamide-urea gel and autoradiography.
Extension of the primer is partially inhibited by the presence of methylated G9 in mt-tRNALeu(UUR) leading to the accumulation of a
single-base extension product (labeled m1G) that is detectable in both control and in case subject RNA at similar levels.
(D) Sequencing error rates at position 9 in mt-tRNAPhe, mt-tRNAVal, and mt-tRNAGlu determined by RNA-seq analysis of mitochondrial
RNAs extracted from control and subjects’ fibroblasts. The relative abundance of individual nucleotides and indels generated by the
presence of m1R9 was analyzed as described previously.7lower steady-state levels in subject fibroblasts relative to
controls.
To further investigate precursor processing, we carried
out RNA-seq analysis of mitochondrial RNA isolated from
control and affected individuals. Differential analyses of
mt-mRNA and mt-tRNA gene expression in TruSeq library
datasets and small RNA library datasets, respectively,
revealed no significant differences in mitochondrially
encodedmt-mRNA,mt-rRNA, andmt-tRNA levels between
the samples (not shown). However, when we investigated
the changes in the abundance of reads across the entire
mitochondrial transcriptome, we found an increase in
the regions that span gene boundaries, where RNA process-
ing is required to release individual mitochondrial RNAs
from the precursor transcripts (Figure S1). Together,
these data confirm an impairment of mt-tRNA processing
efficiency without severe effects on mature mt-mRNA or
mt-tRNA steady-state levels. It is possible that the
cleavage of mt-tRNAs by mt-RNase P is less efficient in
cells harboring TRMT10C/MRPP1 variants, but that the
mt-tRNAs that are cleaved are very stable, thus retaining
steady-state mt-tRNA levels to approximately wild-type
levels.The AmeAll tRNAs undergo post-translational modification at
numerous sites to promote their correct function.11,17 The
mt-tRNAs arenot exceptions and cleavage from thepolycis-
tronic mt-RNA transcripts is just one step in their matura-
tion. In addition to their role in RNase P activity, MRPP1
and MRPP2 act as an m1R9 methyltransferase.14 Methyl-
ation of either G or A at position 9 is vital for the correct
structure and function ofmt-tRNAs.12,13,18 Thus,we sought
to investigate the impact of theTRMT10C variants onm1R9
methyltransferase activity in subject fibroblasts. To this
aim, we utilized two experimental approaches: (1) primer
extension analysis of individual mt-tRNAs during which
the reverse transcriptase-mediated extension of a radiola-
belledprimer is inhibitedby thepresenceofm1R9modifica-
tion19 and (2) RNA-seq analysis, becausem1methylation at
position 9 has been shown to increase the sequencing
error rate at this position.7 Primer extension analysis of
mt-tRNALeu(UUR) revealed no difference between control
subjects and affected individuals (Figure 3C). Similarly,
there was no change in the sequencing error rates between
subject and control samples (Figure 3D). Thesedata indicate
that the m1R9 methyltransferase activity is not affected by
the p.Arg181Leu and p.Thr272Ala MRPP1 variants.rican Journal of Human Genetics 98, 993–1000, May 5, 2016 997
Figure 4. Lentiviral Expression of Wild-
Type TRMT10C Restores RNA Processing,
Expression of mtDNA-Encoded Proteins,
and OXPHOS Assembly in Subjects’ Fibro-
blasts
(A) Western blot analysis of fibroblast ex-
tracts transduced with lentiviral particles
expressing wild-type TRMT10C. MRPP1,
COXI, and SDHA were detected with spe-
cific antisera. SDHA was used as a loading
control.
(B) In vitro mitochondrial translation in
subjects’ fibroblasts transduced with con-
trol lentiviral particles or particles express-
ing wild-type TRMT10C. Analyses were
performed as in Figure 2C.
(C) Blue-native PAGE analysis of OXPHOS
assembly in rescued subjects’ fibroblasts
performed as in Figure 2B, showing restora-
tion of complex assembly.
(D) Northern blot analysis of RNA pro-
cessing in complemented fibroblasts ana-
lyzed as in Figure 3A. For MT-RNR2 (16S
mt-rRNA), short (S) exposure was used
with a long (L) exposure shown to high-
light the weaker band corresponding to
RNA19. Representative images from three
independent lentiviral rescue experiments
are shown for each panel of this figure.We have demonstrated that tRNA 50 processing is
affected in fibroblasts from affected individuals with
mutant MRPP1, which is consistent with current knowl-
edge of the function of MRPP1 as a component of
mt-RNase P. However, to definitively prove that the mito-
chondrial OXPHOS defect is a consequence of the
TRMT10C variants, lentiviral rescue experiments were
performed to complement the respiratory phenotype ex-
pressed in cultured cells. Fibroblast cell lines from affected
individuals were transfected with a lentiviral vector car-
rying a copy of the wild-type TRMT10C gene encoding
MRPP1. The complemented cell lines displayed increased
expression of MRPP1 protein level (Figure 4A), leading to
a restoration of mitochondrial translation (Figures 4A
and 4B) and normal levels of fully assembled respiratory
chain complexes (Figure 4C). Furthermore, the level of
mt-RNA precursors, elevated in subject fibroblasts, normal-
ized after lentiviral transduction with wild-type TRMT10C
(Figure 4D). These data verify the pathogenicity of the
c.542G>T (p.Arg181Leu) and c.814A>G (p.Thr272Ala)
TRMT10C variants, establishing these variants as causative
of mitochondrial disease associated with multiple respira-
tory chain abnormalities.
Prenatal diagnosis has subsequently been offered to both
families in subsequent pregnancies after the identification
and validation of pathogenic TRMT10C variants. In the
first family harboring compound heterozygous changes,
both TRMT10C variants were identified in a later preg-
nancy after chorionic villus biopsy, leading to termination.
In family 2 (homozygous variant), the fetus was heterozy-
gous for the c.542G>T (p.Arg181Leu) TRMT10C variant998 The American Journal of Human Genetics 98, 993–1000, May 5,and mitochondrial respiratory chain activities were
normal in the chorionic villus biopsy sample (data not
shown), supportive of an unaffected clinical status.
Of interest, we noted that both affected individuals
showed decreased MRPP1 steady-state protein levels in fi-
broblasts, although the levels in subject 1 (compound
heterozygote variants) had lower levels than subject 2 (ho-
mozygous variant), suggesting that the p.Thr272Ala
mutant MRPP1 protein is less stable than the p.Arg181Leu
mutant. However, despite having higher residual levels of
MRPP1, cells from subject 2 exhibited a more severe
impairment of mitochondrial protein synthesis resulting
in lower steady-state levels of respiratory chain complexes
I and IV, implying the p.Arg181Leumutant protein is more
stable but less active than the p.Thr272Ala mutant protein.
The impairment ofmt-RNA processing observed in fibro-
blasts from the affected individuals was not as severe as we
anticipated, with steady-state levels of mature mt-mRNAs
and mt-tRNAs largely unaffected. However, these data fit
well with reports of mutations in other proteins involved
with RNA processing, given that mutations in ELAC220
andHSD17B1021 have both been shown to lead to an accu-
mulation of mt-RNA precursors without effects on the
levels of mature mt-mRNA and mt-tRNAs. Furthermore,
it has been shown that loss of MRPP2 levels leads to a
reduction in steady-state levels of MRPP1.21,22 Given that
the increase in RNA precursors (RNA19) we report was
similar to those seen in subjects with deleterious
HSD17B10 (MRPP2) variants (MIM: 300438),21 it is
possible that decreased MRPP1 protein levels are particu-
larly important for RNA processing because MRPP2 levels2016
were not shown to be diminished in either of the cases
documented here (Figure 2B). Conversely, we did not
find any evidence of altered m1R9 methyltransferase activ-
ity in fibroblasts from either affected individual, implying
that the observed defect in mitochondrial protein synthe-
sis is due to a decrease in the efficiency of mt-RNA process-
ing rather than any effects on mt-tRNA modification. The
m1R9 methyltransferase activity is carried out by a stable
protein complex of MRPP1 and MRPP2,14 whereas the
RNA processing requires MRPP3,6 which contains the
active site of the nuclease activity of RNase P.23,24 There-
fore, one attractive hypothesis is to suggest that the
p.Arg181Leu and p.Thr272Ala TRM10C variants disrupt
the interaction between MRPP1 and MRPP3 without
affecting the complex with MRPP2, although this requires
future investigation.
Knowledge of defects in mt-tRNA processing or modifi-
cation leading to disease has expanded in recent years
including the aforementioned variants in HSD17B10
(MRPP2)21 and ELAC2,20 as well as mutations in numerous
mt-tRNA modifier proteins including PUS125 (MIM:
608109), TRIT1,26 TRMU27 (MIM: 610230), TRNT128
(MIM: 612907), TRMT519 (MIM: 611023), MTO129,30
(MIM: 614667), and GTPBP331 (MIM: 608536). Mutations
in TRMT10C (MRPP1) can now be added to this growing
list as we show that the introduction of wild-type MRPP1
into fibroblasts from affected individuals is sufficient to
rescue their mitochondrial defects, confirming these
TRMT10C variants as pathogenic in mitochondrial disease
associated with impaired mitochondrial translation.Accession Numbers
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